1-[(3,4-dichlorophenyl)methyl]-2,1,3-benzothiadiazin-4(3H)-one 2,2-dioxide | 261900-50-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[(3,4-dichlorophenyl)methyl]-2,1,3-benzothiadiazin-4(3H)-one 2,2-dioxide
• 英文别名: 1-[(3,4-dichlorophenyl)-methyl]-2,1,3-benzothiadiazin-4(3H)-one 2,2-dioxide；1-[(3,4-dichlorophenyl)methyl]-2,2-dioxo-2λ6,1,3-benzothiadiazin-4-one
• CAS: 261900-50-9
• 化学式: C₁₄H₁₀Cl₂N₂O₃S
• 分子量: 357.217
• InChiKey: ROGLPPVVAYRNNA-UHFFFAOYSA-N

物化性质

• 熔点：
  250-252 °C
• 密度：
  1.562±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  溴甲基环己烷 、 1-[(3,4-dichlorophenyl)methyl]-2,1,3-benzothiadiazin-4(3H)-one 2,2-dioxide 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 以2%的产率得到4-Cyclohexylmethoxy-1-(3,4-dichloro-benzyl)-1H-benzo[1,2,6]thiadiazine 2,2-dioxide
  参考文献：
  名称：

  Benzothiadiazine dioxides (BTD) derivatives as non-nucleoside human cytomegalovirus (HCMV) inhibitors. study of structural requirements for biological activity☆

  摘要：

  Two new series of BTD derivatives have been synthesised allowing to explore the steric requirements for their biological activity. The N3-alkylBTD compounds have shown antiviral activity in the same order or lower than previously prepared compounds. However, the cytotoxicity values observed prevent this new series of BTD derivatives from its potential therapeutic application. Concerning BTD derivatives with the modified linker attached to N1 position, we have obtained new non-nucleoside anti-HCMV derivatives. The activity against HCMV is shown at concentrations that were 10-fold lower than the concentration that was toxic for the host cells, which confirm that these derivatives show a specific antiviral effect against HCMV. SAR conclusions derived from these last compounds have provided new knowledge about the structural requirements of BTD showing certain positions that could be modified for enhancing the anti-HCMV action. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00148-2
• 作为产物：
  描述：

  3,4-二氯氯苄 、 4-hydroxy-2,1,3-benzothiadiazine 2,2-dioxide 在 碳酸氢钠 作用下， 反应 2.0h， 以76%的产率得到1-[(3,4-dichlorophenyl)methyl]-2,1,3-benzothiadiazin-4(3H)-one 2,2-dioxide
  参考文献：
  名称：

  Benzyl Derivatives of 2,1,3-Benzo- and Benzothieno[3,2-a]thiadiazine 2,2-Dioxides:  First Phosphodiesterase 7 Inhibitors

  摘要：

  The synthesis of a new family of benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]-thiadiazine 2,2-dioxides was achieved. The biological data revealed the first heterocyclic family of compounds with PDE 7 inhibitory properties appearing to be a new objective for the treatment of T-cell-dependent disorders. The IC50 values or percent inhibition values of the compounds against PDE 7 were calculated by testing them against human recombinant PDE 7 expressed in S, cerevisiae. In this expression system the only cyclic nucleotide hydrolyzing activity present in cell extracts corresponded to human PDE 7. Isoenzyme selectivity PDE 7 versus PDE 4 and PDE 3 was also measured. Considering simultaneously inhibition of the three different isoenzymes, monobenzyl derivatives 15 and 23 showed interesting PDE 7 potency (around 10 mu M); although not statistically significant, a trend toward selectivity with respect to PDE 3 and PDE 4 was obtained. Benzothiadiazine 16, although less potent at PDE 7 (IC50 25 mu M), also showed a trend of selectivity toward PDE 3 and PDE 4. These compounds are considered the best leads for further optimization.

  DOI：

  10.1021/jm990382n

文献信息

• Nonnucleoside Human Cytomegalovirus Inhibitors:  Synthesis and Antiviral Evaluation of (Chlorophenylmethyl)benzothiadiazine Dioxide Derivatives
  作者：Ana Martinez、Carmen Gil、Concepción Perez、Ana Castro、Columbiana Prieto、Joaquín Otero、Graciela Andrei、Robert Snoeck、Jan Balzarini、Erik De Clercq

  DOI：10.1021/jm000118q

  日期：2000.8.1

  A second generation of benzothiadiazine dioxide (BTD) derivatives was synthesized employing benzylation reactions mainly. The chlorophenylmethyl BTD derivatives showed activity against human cytomegalovirus (HCMV) with IC(50) values ranging from 3 to 10 microM. Their 50% cytotoxic concentrations were often >200 microM to lung fibroblast HEL cell proliferation and between 20 and 35 microM for lymphocyte

  主要利用苄基化反应合成了第二代苯并噻二嗪二氧化物（BTD）衍生物。氯苯基甲基BTD衍生物具有抗人巨细胞病毒（HCMV）的活性，IC（50）值为3至10 microM。它们对肺成纤维细胞HEL细胞增殖的50％细胞毒性浓度通常> 200 microM，而淋巴细胞CME细胞的生长浓度在20至35 microM之间。考虑细胞形态的细胞毒性时，不同BTD衍生物的最小细胞毒性浓度在5到200 microM之间变化。一些抗HCMV化合物还显示出抗HIV-1和HIV-2的活性。氯苯基甲基衍生物21对多种来自具有不同临床表现的患者的HCMV临床分离株具有活性，并完全保持了其对更昔洛韦耐药的HCMV株的活性。二苄基BTD衍生物不抑制HCMV蛋白酶，初步的药理实验表明，它们的抗HCMV作用源于对病毒复制周期早期的干扰。
• Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
  申请人：OMEROS CORPORATION

  公开号：US20130267502A1

  公开（公告）日：2013-10-10

  This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.

  本公开涉及使用磷酸二酯酶7（PDE7）抑制剂，单独或与其他治疗药物联合治疗成瘾和原发性冲动控制障碍。
• Use of PDE7 Inhibitors for the Treatment of Movement Disorders
  申请人：OMEROS CORPORATION

  公开号：US20140179717A1

  公开（公告）日：2014-06-26

  A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.

  一种治疗神经运动障碍病理学相关的运动异常的方法，例如帕金森病或不宁腿综合症，通过给予治疗有效量的PDE7抑制剂。该发明的一个方面是在给予多巴胺激动剂或前体（如左旋多巴）的同时给予PDE7抑制剂。在该发明的另一个方面，PDE7抑制剂可以相对于其他分子靶点（i）已知与帕金森病的病理学有关或（ii）其他治疗帕金森病有效的药物作用的靶点而选择性地作用于PDE7。
• USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS
  申请人：Omeros Corporation

  公开号：US20160015715A1

  公开（公告）日：2016-01-21

  A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.

  本发明涉及一种治疗神经运动障碍病理学相关的运动异常的方法，例如帕金森病或不宁腿综合症，通过给予治疗有效量的PDE7抑制剂。本发明的一个方面提供了与多巴胺激动剂或前体（例如左旋多巴）一起给予PDE7抑制剂的治疗方法。在本发明的另一个方面，PDE7抑制剂可以选择性地作用于PDE7，而相对于其他分子靶点（i）已知与帕金森病的病理学有关或（ii）其他治疗帕金森病的药物作用的靶点。
• Treatment of addiction and impulse-control disorders using PDE7 inhibitors
  申请人：Omeros Corporation

  公开号：US11207275B2

  公开（公告）日：2021-12-28

  This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.

  本公开内容涉及使用磷酸二酯酶 7 (PDE7) 抑制剂单独或与其他治疗剂联合治疗成瘾症和原发性冲动控制障碍。